Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Rilzabrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 13,206Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi's Rilzabrutinib Designated Breakthrough Therapy In US
    Sanofi's Rilzabrutinib Designated Breakthrough Therapy In US

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234232/0/en/Press-Release-Sanofi-s-rilzabrutinib-designated-breakthrough-therapy-in-the-US-and-orphan-drug-in-Japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    EU Approves Sanofi's Wayrli as First BTK Inhibitor for ITP
    EU Approves Sanofi's Wayrli as First BTK Inhibitor for ITP

    23 Dec 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-12-23-14-06-58-3209943

    PRESS RELEASE
    23 Dec 2025
    Share Share
    Sanofi's Wayrilz Recommended For EU Approval For thrombocytopenia
    Sanofi's Wayrilz Recommended For EU Approval For thrombocytopenia

    17 Oct 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-17-11-05-00-3168539

    PRESS RELEASE
    17 Oct 2025
    Share Share
    Onco360® Chosen as National Pharmacy Partner for Wayrilz
    Onco360® Chosen as National Pharmacy Partner for Wayrilz

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3146482/0/en/Onco360-Has-Been-Selected-as-a-National-Specialty-Pharmacy-Partner-for-Wayrilz-rilzabrutinib.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Sanofi's Wayrilz FDA Approved as First BTK Inhibitor for Immune
    Sanofi's Wayrilz FDA Approved as First BTK Inhibitor for Immune

    29 Aug 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-29-21-50-18-3141825

    PRESS RELEASE
    29 Aug 2025
    Share Share
    Genzyme's Wayrilz Receives Approval in US
    Genzyme's Wayrilz Receives Approval in US

    29 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219685

    FDA
    29 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.